Peptides in South Carolina: Research, Regulation and Where the Law Stands

Searches for "peptides South Carolina" usually mix several different questions together: what the science says about a given peptide, whether a compound has been approved by the U.S. Food and Drug Administration, what "research use only" means on a vial label, and which agency in Columbia or Washington would be the one to care. Those are separate systems, and they overlap rather than stack neatly. This page describes each layer and who administers it.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here is legal advice — it is a description of publicly documented regulatory structures, not an opinion about whether any particular activity, product or arrangement complies with state or federal law. Statutes, board regulations and FDA guidance change, and only a licensed South Carolina attorney can advise on a specific situation.

The Federal Layer Comes First

Most of what determines how a peptide can lawfully be manufactured, labelled, prescribed or dispensed is federal, not state. The Federal Food, Drug, and Cosmetic Act defines what counts as a drug, what counts as an approved drug, and what happens to everything else.

Approved peptide drugs

A meaningful number of peptides have been through the full approval pathway. A review of the 2017 approval cohort catalogued the peptide and peptide-like new molecular entities cleared by the FDA in that single year and described their chemical classes and therapeutic targets, illustrating that peptides are an established drug class rather than a fringe one (PMID 29735913). Approved products carry FDA-reviewed labelling, a defined manufacturing standard, and post-marketing surveillance obligations.

A 2026 review in Sports Medicine examined both approved and unapproved peptide therapies marketed for musculoskeletal injury and athletic performance, and the authors reported that the evidence base for many of the unapproved agents was thinner than their marketing implied (PMID 41966639). That distinction — approved versus circulating-but-unapproved — is the single most useful line to keep in mind when reading anything about peptides, in South Carolina or anywhere else.

"Research use only" materials

Many peptides discussed online are supplied as research chemicals under research-use-only (RUO) labelling. RUO material is, by its own labelling, not intended for human or veterinary use, is not manufactured under drug current good manufacturing practice requirements, and has not been evaluated by the FDA for safety or efficacy in people. The RUO designation is a statement about intended use and manufacturing standard. When a product's actual marketing or presentation suggests human therapeutic use, federal authorities have treated that presentation, rather than the fine print, as determining the product's regulatory status. Enforcement in this space is led by the FDA, and marketing claims can additionally draw attention from the Federal Trade Commission.

Compounding: The 503A / 503B Distinction

Compounding is the area where the most confusion arises, because compounded preparations are lawful drugs made outside the approval system.

Both categories are constrained in how far they may compound something that is essentially a copy of a commercially available approved drug, and both are constrained in which bulk drug substances they may use. Drug shortages have historically changed that calculus temporarily; when the FDA determines a shortage has resolved, the latitude narrows again. Readers tracking this should consult FDA's current shortage list and bulk-substance lists directly rather than relying on secondary summaries.

What studies report about compounded peptide products

Compounded versions of GLP-1 receptor agonists have been studied directly. An analytical investigation compared follow-on GLP-1 polypeptide products and reported that manufacturing route and compounding processes influenced physicochemical properties and quality attributes of the resulting products (PMID 39379664). Separately, a real-world study described weight loss and body-composition changes in patients treated with compounded semaglutide in routine practice, and the authors framed the work as an observational description of an unapproved-product setting rather than a controlled efficacy trial (PMID 39776038). Neither study addressed South Carolina specifically, and neither offered a legal characterisation of compounding practices.

Telehealth Prescribing

Peptide-adjacent prescribing frequently reaches patients through telehealth platforms, which introduces a third layer: a prescriber must generally hold a licence in the state where the patient is located at the time of the encounter, and must meet that state's standard for establishing a valid practitioner–patient relationship. Federal controlled-substance rules add further requirements, though most peptides discussed in this context are not controlled substances. Where a peptide is not an approved drug at all, the question shifts from telehealth rules to whether the substance can be prescribed or dispensed as a drug in the first place.

What Is Specific to South Carolina

The South Carolina Board of Pharmacy

Pharmacists, pharmacies and pharmacy permits in South Carolina are regulated by the South Carolina Board of Pharmacy, which sits within the South Carolina Department of Labor, Licensing and Regulation (LLR). The board administers the state's Pharmacy Practice Act, codified in Title 40, Chapter 43 of the South Carolina Code of Laws, and promulgates regulations covering licensure, inspection, discipline and pharmacy practice standards — including the standards applicable to compounding pharmacies operating in the state and, in many cases, to out-of-state pharmacies shipping into it. Readers should consult the board's current regulations and the code text directly, since board rules are revised on their own schedule.

The South Carolina Board of Medical Examiners

Physicians and physician assistants are licensed by the South Carolina Board of Medical Examiners, also administered through LLR, under the Medical Practice Act at Title 40, Chapter 47 of the South Carolina Code of Laws. That chapter includes South Carolina's statutory telemedicine provisions, which set out expectations for licensure and for the establishment of a physician–patient relationship when care is delivered remotely. Prescribing decisions by South Carolina-licensed physicians — including decisions involving off-label or compounded products — fall within that board's disciplinary jurisdiction, alongside any federal authority that may apply.

Other South Carolina bodies that can be involved

• South Carolina Department of Health and Environmental Control / its successor agencies — historically involved in drug control and food, drug and cosmetic matters at state level.
• South Carolina Attorney General's Office — consumer protection enforcement under the state's Unfair Trade Practices Act, Title 39, Chapter 5.
• Other LLR-housed boards — for nurses, physician assistants and other licensed professionals who may be involved in prescribing or administration.

Where nothing state-specific is verifiable

It is worth being blunt about the limits here. There is no South Carolina statute that carves out "peptides" as a distinct legal category, and none of the peptide studies summarised on this page were conducted in, or restricted to, South Carolina. Claims circulating online that a particular peptide is "legal in South Carolina" or subject to some unique state rule generally have no citable source behind them. Where this page cannot point to a specific South Carolina provision, it says so rather than inventing one. The practical result is that the federal layer — approval status, unapproved-drug rules, compounding limits — usually does more work than the state layer, with the state boards governing the conduct of licensees.

Adverse Events in the Peptide Literature: What Studies Report

Regulatory structure exists partly because of safety signals, and the largest body of peptide safety data comes from pharmacovigilance analyses of GLP-1 receptor agonists. These are disproportionality analyses of spontaneous reports; they identify statistical signals and cannot establish causation or incidence.

• Gastrointestinal events. Analyses of the FDA Adverse Event Reporting System reported disproportionate reporting of gastrointestinal events such as nausea, vomiting, diarrhoea and constipation with semaglutide (PMID 36339230), and a comparative study across several GLP-1 receptor agonists reported differences between agents in gastrointestinal reporting patterns (PMID 36568085).
• Broader semaglutide profile. A post-marketing disproportionality analysis described the range of reported events associated with semaglutide across organ systems (PMID 38943656).
• Tirzepatide. Researchers analysing FAERS data reported a real-world safety profile for tirzepatide, again dominated by gastrointestinal reports (PMID 39141075).
• Metabolic and nutritional events. A pharmacovigilance study examined metabolic and nutritional adverse events reported with GLP-1 receptor agonists as a class (PMID 39040467).
• Pancreatitis. A case series combined with real-world pharmacovigilance analysis examined acute pancreatitis reports across different GLP-1 receptor agonists (PMID 39605914).
• Psychiatric events. An analysis of EudraVigilance case safety reports examined psychiatric adverse events reported with semaglutide, liraglutide and tirzepatide (PMID 38265519), and a separate FAERS-based study explored potential associations with suicidal or self-injurious behaviours (PMID 38355513).

The study designs above share a common limitation the authors themselves emphasised: spontaneous reporting databases are subject to under-reporting, reporting bias and missing denominators. For unapproved and research-use-only peptides, there is generally no comparable surveillance system at all, which is one reason the 2026 musculoskeletal review characterised the safety evidence for many such agents as limited (PMID 41966639).

Who Enforces What

Reading the Evidence Carefully

Three habits help when evaluating peptide claims framed around a state. First, check whether a compound is an approved drug, a compounded preparation, or an unapproved research chemical, because each sits under a different rule set. Second, distinguish signal-generating pharmacovigilance work from controlled trials — the FAERS and EudraVigilance analyses cited above describe what was reported, not what was caused. Third, treat any "legal in South Carolina" claim as requiring a citation to an actual statute, regulation or board position; absent that, it is an assertion rather than a fact. For questions about a specific product, arrangement or clinical situation, licensed South Carolina professionals — a physician, a pharmacist, or an attorney — are the appropriate sources.

References

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• 2017 FDA Peptide Harvest (Pharmaceuticals, 2018)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• Weight loss and body composition after compounded semaglutide treatment in a real world setting (Diabetes, Obesity & Metabolism, 2025)
• Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (Frontiers in Public Health, 2022)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data (Journal of Diabetes Investigation, 2024)
• The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (Journal of Endocrinological Investigation, 2024)
• Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events (Frontiers in Pharmacology, 2024)
• Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis (Frontiers in Pharmacology, 2024)
• Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database (International Journal of Clinical Pharmacy, 2024)
• Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database (BMC Medicine, 2024)